Product image of Mifoglame (Sitagliptin) supplied by GNH India

Mifoglame

Active Ingredient:
Sitagliptin
Origin:
EU

Mifoglame (Sitagliptin)

Sitagliptin, the active ingredient in Mifoglame, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus by enhancing insulin secretion and reducing glucagon release.

GNH India supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU GMP standards and offers comprehensive logistics solutions.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifoglame (sitagliptin) acts on the incretin pathway to manage hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction when metformin alone is insufficient.
  • Type 2 diabetes mellitus (combined with insulin or sulfonylureas): helps achieve target glycaemic control while minimizing insulin dose.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, sitagliptin prolongs the activity of these hormones, leading to glucose‑dependent stimulation of insulin secretion from pancreatic β‑cells and suppression of glucagon release from α‑cells, thereby reducing blood glucose concentrations. The effect is glucose‑dependent, minimizing risk of hypoglycaemia when used without other insulin‑secretagogues, and it has limited interaction with CYP enzymes.

Side Effects

Sitagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nose and throat.
  • Headache: transient cranial pain.
  • Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema or anaphylaxis.
  • Joint pain: unexplained arthralgia that may be persistent.

Precautions & Warnings

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: monitor liver enzymes during therapy.
  • History of pancreatitis: avoid use due to increased risk.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Avoid Interactions

Sitagliptin may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure.
  • Co‑administration with insulin or sulfonylureas: can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce sitagliptin plasma levels.
  • Diuretics: may affect glucose control and require monitoring.
  • ACE inhibitors: may increase risk of hypotension when combined with antihypertensives.

Frequently Asked Questions

Mifoglame contains the active ingredient sitagliptin and is indicated for the management of type 2 diabetes mellitus. It is used to improve glycaemic control either as a stand‑alone therapy or in combination with other antidiabetic agents such as metformin, sulfonylureas or insulin.

Sitagliptin works by selectively inhibiting the dipeptidyl peptidase‑4 (DPP‑4) enzyme. This inhibition prolongs the activity of the incretin hormones GLP‑1 and GIP, which enhances glucose‑dependent insulin secretion from pancreatic β‑cells and suppresses glucagon release, leading to lower blood glucose levels.

The appropriate dose of Mifoglame is determined by the prescribing clinician based on the individual patient's clinical condition, renal function and concomitant therapies. The prescriber will select the dose that best balances efficacy and safety for each patient.

Safety of sitagliptin in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Mifoglame, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and the necessary import documentation.

Mifoglame (sitagliptin) belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin release with a low risk of hypoglycaemia when used alone. Compared with sulfonylureas, it has a more favourable hypoglycaemia profile, and unlike GLP‑1 receptor agonists, it is administered orally rather than by injection.

Mifoglame tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure that it is out of reach of children.

Mifoglame is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, according to the prescribing clinician’s instructions.

The most serious risks include acute pancreatitis, severe allergic reactions such as anaphylaxis, and joint pain that may be persistent. Patients should seek immediate medical attention if they experience severe abdominal pain, rash, swelling of the face or limbs, or unexplained arthralgia.

Mifoglame should not be used by individuals with a known hypersensitivity to sitagliptin or any component of the formulation, by patients with a history of pancreatitis, and by those with severe renal impairment unless dose adjustments are made under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT